Gregory Bell

Gregory Bell, M.D. earned his medical degree from Cornell University Medical College and completed his training in Internal Medicine and Rheumatology at Brown University and the University of California, San Francisco (UCSF), respectively.

In 1996, he joined Merck & Co., Inc and contributed to several products that received regulatory approval including Vioxx®, Etoricoxib® and Cancidas®. Greg returned to California in 2000, joined Abgenix, Inc. and became Vice President of Clinical Development, Biometrics and Clinical Operations with responsibilities across the portfolio including Vectibix®. In 2005 Greg joined KAI Pharmaceuticals as Senior Vice President, Development and Chief Medical Officer. While at KAI he discovered peptide agonists of the calcium sensing receptor and led the global development of Parsabiv® until Amgen acquired KAI in 2012. In 2013 Dr. Bell joined Genentech as Vice President, Safety Risk Management of the Immunology, Infectious Disease and Ophthalmology portfolio. While at Genentech, Greg built and led a team that supported over a dozen different clinical programs and contributed to multiple NME and supplemental global filings across the portfolio.

Prior to joining Attralus, Greg was SVP of Development at Global Blood Therapeutics. Dr. Bell is an Assistant Clinical Professor of Medicine at UCSF and is a member of the American College of Rheumatology.